Chemistry:Luvometinib
From HandWiki
Luvometinib is a drug for the treatment of various types of cancer. It is a selective, orally administered inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/MEK2), developed by Fosun Pharma for the treatment of rare malignancies, especially those driven by abnormal abnormal mitogen-activated protein kinase (MAPK) activation.[1][2]
In May 2025, it was approved in China for the treatment of histiocytic neoplasms such as Langerhans cell histiocytosis (LCH) and the genetic disease neurofibromatosis type 1 (NF1).[2]
References
- ↑ "Current Development Status of MEK Inhibitors". Molecules (Basel, Switzerland) 22 (10): 1551. 2017. doi:10.3390/molecules22101551. PMID 28954413.
- ↑ 2.0 2.1 "Luvometinib: First Approval". Drugs. 2025. doi:10.1007/s40265-025-02217-6. PMID 40751881.
 |  |
